[The filter region of the myocardial Na channel, together with ion selectivity, controls pharmacodynamics of anti-arrhythmia agents--an analysis using the channel altered by idiopathic ventricular fibrillation].
Sasaki
Koji
K
D000889:Anti-Arrhythmia Agents / Q000493:pharmacokinetics*; D005374:Filtration; D006321:Heart / Q000503:physiopathology; D006801:Humans; D066298:In Vitro Techniques; D008012:Lidocaine / Q000031:analogs & derivatives* / Q000494:pharmacology; D008801:Mexiletine / Q000494:pharmacology; D009124:Muscle Proteins / Q000235:genetics*; D062554:NAV1.5 Voltage-Gated Sodium Channel; D015222:Sodium Channels / Q000235:genetics* / Q000502:physiology*; D014693:Ventricular Fibrillation / Q000503:physiopathology*
D000889:Anti-Arrhythmia Agents; D009124:Muscle Proteins; D062554:NAV1.5 Voltage-Gated Sodium Channel; C568320:SCN5A protein, human; D015222:Sodium Channels; D008801:Mexiletine; C012647:QX-314; D008012:Lidocaine